According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. A bioprocess international European summit was held in Vienna, Austria during which delegates were told that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for Haemophilia last September – had required a considerable process development effort. In his statement, he clarified by saying “There are no more classical standard approaches…
Read MoreThe Bispecific and Complex mAbs Driving Process Development Innovation, Roche
